Abstract
Hypoxia is widely recognised as a key driving force for tumour angiogenesis by its induction of vascular endothelial growth factor (VEGF) and other direct-acting angiogenic factors. We describe the effect of hypoxia on gene expression and downstream angiogenic signalling; however, the angiogenic process is complex, and many other signalling pathways beyond VEGF are implicated in the formation of new vessels. These include extra-cellular signalling pathways such as the notch/delta, ephrin/Eph receptor, roundabout/slit, and netrin/UNC (uncoordinated) receptor families as well as intracellular proteins such as hedgehog and sprouty. The remarkable diversity in angiogenic signalling pathways provides many opportunities for therapeutic intervention, and anti-angiogenesis is currently a major area of oncology research.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Eskens, F. A. (2004) Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 90, 1–7.
Tonini, T., Rossi, F., Claudio, P. P. (2003) Molecular basis of angiogenesis and cancer. Oncogene 22, 6549–6556.
Bicknell, R., Harris, A. L. (2004) Novel angiogenic signaling pathways and vascular targets. Annu Rev Pharmacol Toxicol 44, 219–238.
Sullivan, D. C., Bicknell, R. (2003) New molecular pathways in angiogenesis. Br J Cancer 89, 228–231.
Carmeliet, P. (2003) Blood vessels and nerves: common signals, pathways and diseases. Nat Rev Genet 4, 710–720.
Martin, P., Lewis, J. (1989) Origins of the neurovascular bundle: interactions between developing nerves and blood vessels in embryonic chick skin. Int J Dev Biol 33, 379–387.
Honma, Y., Araki, T., Gianino, S., (2002) Artemin is a vascular-derived neurotropic factor for developing sympathetic neurons. Neuron 35, 267–282.
Kuruvilla, R., Zweifel, L. S., Glebova, N. O., (2004) A neurotrophin signaling cascade coordinates sympathetic neuron development through differential control of TrkA trafficking and retrograde signaling. Cell 118, 243–255.
Mukouyama, Y. S., Shin, D., Britsch, S., Taniguchi, M., Anderson, D. J. (2002) Sensory nerves determine the pattern of arterial differentiation and blood vessel branching in the skin. Cell 109, 693–705.
Harris, A. L. (2002) Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2, 38–47.
Wenger, R. H. (2002) Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 16, 1151–1162.
Ivan, M., Kondo, K., Yang, H., (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464–468.
Leek, R. D., Talks, K. L., Pezzella, F., (2002) Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Res 62, 1326–1329.
Pilch, H., Schlenger, K., Steiner, E., Brockerhoff, P., Knapstein, P., Vaupel, P. (2001) Hypoxia-stimulated expression of angiogenic growth factors in cervical cancer cells and cervical cancer-derived fibroblasts. Int J Gynecol Cancer 11, 137–142.
Ozawa, K., Kondo, T., Hori, O., (2001) Expression of the oxygen-regulated protein ORP150 accelerates wound healing by modulating intracellular VEGF transport. J Clin Invest 108, 41–50.
Shimo, T., Kubota, S., Kondo, S., (2001) Connective tissue growth factor as a major angiogenic agent that is induced by hypoxia in a human breast cancer cell line. Cancer Lett 174, 57–64.
Kondo, S., Kubota, S., Shimo, T., (2002) Connective tissue growth factor increased by hypoxia may initiate angiogenesis in collaboration with matrix metalloproteinases. Carcinogenesis 23, 769–776.
Ambrosini, G., Nath, A. K., Sierra-Honigmann, M. R., Flores-Riveros, J. (2002) Transcriptional activation of the human leptin gene in response to hypoxia. Involvement of hypoxia-inducible factor 1. J Biol Chem 277, 34601–34609.
Hitchon, C., Wong, K., Ma, G., Reed, J., Lyttle, D., El-Gabalawy, H. (2002) Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum 46, 2587–2597.
Bacher, M., Schrader, J., Thompson, N., (2003) Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme. Am J Pathol 162, 11–17.
Green, C. J., Lichtlen, P., Huynh, N. T., (2001) Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. Cancer Res 61, 2696–2703.
Murray, B., Wilson, D. J. (2001) A study of metabolites as intermediate effectors in angiogenesis. Angiogenesis 4, 71–77.
Senger, D. R., Connolly, D. T., Van de Water, L., Feder, J., Dvorak, H. F. (1990) Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 50, 1774–1778.
Shweiki, D., Itin, A., Soffer, D., Keshet, E. (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843–845.
Olsson, A. K., Dimberg, A., Kreuger, J., Claesson-Welsh, L. (2006) VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7, 359–371.
Fong, G. H., Rossant, J., Gertsenstein, M., Breitman, M. L. (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66–70.
Kendall, R. L., Thomas, K. A. (1993) Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 90, 10705–10709.
Goldman, C. K., Kendall, R. L., Cabrera, G., (1998) Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, mortality rate. Proc Natl Acad Sci U S A 95, 8795–8800.
Autiero, M., Waltenberger, J., Communi, D., (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9, 936–943.
Hiratsuka, S., Maru, Y., Okada, A., Seiki, M., Noda, T., Shibuya, M. (2001) Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 61, 1207–1213.
Dougher, M., Terman, B. I. (1999) Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene 18, 1619–1627.
Takahashi, T., Yamaguchi, S., Chida, K., Shibuya, M. (2001) A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 20, 2768–2778.
Sakurai, Y., Ohgimoto, K., Kataoka, Y., Yoshida, N., Shibuya, M. (2005) Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc Natl Acad Sci U S A 102, 1076–1081.
Matsumoto, T., Bohman, S., Dixelius, J., (2005) VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO J 24, 2342–2353.
Zeng, H., Sanyal, S., Mukhopadhyay, D. (2001) Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. J Biol Chem 276, 32714–32719.
Kaipainen, A., Korhonen, J., Mustonen, T., (1995) Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 92, 3566–3570.
Jussila, L., Alitalo, K. (2002) Vascular growth factors and lymphangiogenesis. Physiol Rev 82, 673–700.
Dumont, D. J., Jussila, L., Taipale, J., (1998) Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282, 946–949.
Valtola, R., Salven, P., Heikkila, P., (1999) VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 154, 1381–1390.
Partanen, T. A., Alitalo, K., Miettinen, M. (1999) Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 86, 2406–2412.
Wang, J. F., Zhang, X., Groopman, J. E. (2004) Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress. J Biol Chem 279, 27088–27097.
Makinen, T., Veikkola, T., Mustjoki, S., (2001) Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 20, 4762–4773.
Walter, J. W., North, P. E., Waner, M., (2002) Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer 33, 295–303.
Stevens, A., Soden, J., Brenchley, P. E., Ralph, S., Ray, D. W. (2003) Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63, 812–816.
Bajou, K., Masson, V., Gerard, R. D., (2001) The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 152, 777–784.
Luttun, A., Tjwa, M., Moons, L., (2002) Revascularization of ischemic tissues by PlGF treatment, inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8, 831–840.
Pipp, F., Heil, M., Issbrucker, K., (2003) VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ Res 92, 378–385.
Adini, A., Kornaga, T., Firoozbakht, F., Benjamin, L. E. (2002) Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res 62, 2749–2752.
Eriksson, A., Cao, R., Pawliuk, R., (2002) Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 1, 99–108.
Barbera-Guillem, E., Nyhus, J. K., Wolford, C. C., Friece, C. R., Sampsel, J. W. (2002) Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res 62, 7042–7049.
Pasterkamp, R. J., Kolodkin, A. L. (2003) Semaphorin junction: making tracks toward neural connectivity. Curr Opin Neurobiol 13, 79–89.
Kruger, R. P., Aurandt, J., Guan, K. L. (2005) Semaphorins command cells to move. Nat Rev Mol Cell Biol 6, 789–800.
Guttmann-Raviv, N., Kessler, O., Shraga-Heled, N., Lange, T., Herzog, Y., Neufeld, G. (2006) The neuropilins and their role in tumorigenesis and tumor progression. Cancer Lett 231, 1–11.
Bagri, A., Tessier-Lavigne, M. (2002) Neuropilins as Semaphorin receptors: in vivo functions in neuronal cell migration and axon guidance. Adv Exp Med Biol 515, 13–31.
Song, H., Ming, G., He, Z., (1998) Conversion of neuronal growth cone responses from repulsion to attraction by cyclic nucleotides. Science 281, 1515–1518.
de Castro, F., Hu, L., Drabkin, H., Sotelo, C., Chedotal, A. (1999) Chemoattraction and chemorepulsion of olfactory bulb axons by different secreted semaphorins. J Neurosci 19, 4428–4436.
Wong, J. T., Wong, S. T., O’Connor, T. P. (1999) Ectopic semaphorin-1a functions as an attractive guidance cue for developing peripheral neurons. Nat Neurosci 2, 798–803.
Bagnard, D., Lohrum, M., Uziel, D., Puschel, A. W., Bolz, J. (1998) Semaphorins act as attractive and repulsive guidance signals during the development of cortical projections. Development 125, 5043–5053.
Miao, H. Q., Soker, S., Feiner, L., Alonso, J. L., Raper, J. A., Klagsbrun, M. (1999) Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 146, 233–242.
Miao, H. Q., Lee, P., Lin, H., Soker, S., Klagsbrun, M. (2000) Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J 14, 2532–2539.
Tse, C., Xiang, R. H., Bracht, T., Naylor, S. L. (2002) Human Semaphorin 3B (SEMA3B) located at chromosome 3p21.3 suppresses tumor formation in an adenocarcinoma cell line. Cancer Res 62, 542–546.
Xiang, R., Davalos, A. R., Hensel, C. H., Zhou, X. J., Tse, C., Naylor, S. L. (2002) Semaphorin 3F gene from human 3p21.3 suppresses tumor formation in nude mice. Cancer Res 62, 2637–2643.
Roche, J., Boldog, F., Robinson, M., (1996) Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene 12, 1289–1297.
Brambilla, E., Constantin, B., Drabkin, H., Roche, J. (2000) Semaphorin SEMA3F localization in malignant human lung and cell lines: a suggested role in cell adhesion and cell migration. Am J Pathol 156, 939–950.
Bielenberg, D. R., Hida, Y., Shimizu, A., (2004) Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest 114, 1260–1271.
Neufeld, G., Shraga-Heled, N., Lange, T., Guttmann-Raviv, N., Herzog, Y., Kessler, O. (2005) Semaphorins in cancer. Front Biosci 10, 751–760.
Kessler, O., Shraga-Heled, N., Lange, T., (2004) Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res 64, 1008–1015.
Ochi, K., Mori, T., Toyama, Y., Nakamura, Y., Arakawa, H. (2002) Identification of semaphorin3B as a direct target of p53. Neoplasia 4, 82–87.
Xu, X. M., Fisher, D. A., Zhou, L., (2000) The transmembrane protein semaphorin 6A repels embryonic sympathetic axons. J Neurosci 20, 2638–2648.
Dhanabal, M., Wu, F., Alvarez, E., (2005) Recombinant semaphorin 6A-1 ectodomain inhibits in vivo growth factor and tumor cell line-induced angiogenesis. Cancer Biol Ther 4, 659–668.
Kolodkin, A. L., Levengood, D. V., Rowe, E. G., Tai, Y. T., Giger, R. J., Ginty, D. D. (1997) Neuropilin is a semaphorin III receptor. Cell 90, 753–762.
Kawasaki, T., Kitsukawa, T., Bekku, Y., (1999) A requirement for neuropilin-1 in embryonic vessel formation. Development 126, 4895–4902.
Soker, S., Takashima, S., Miao, H. Q., Neufeld, G., Klagsbrun, M. (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735–745.
Rossignol, M., Gagnon, M. L., Klagsbrun, M. (2000) Genomic organization of human neuropilin-1 and neuropilin-2 genes: identification and distribution of splice variants and soluble isoforms. Genomics 70, 211–222.
Gagnon, M. L., Bielenberg, D. R., Gechtman, Z., (2000) Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: in vivo expression and antitumor activity. Proc Natl Acad Sci U S A 97, 2573–2578.
Yamada, Y., Takakura, N., Yasue, H., Ogawa, H., Fujisawa, H., Suda, T. (2001) Exogenous clustered neuropilin 1 enhances vasculogenesis and angiogenesis. Blood 97, 1671–1678.
Gluzman-Poltorak, Z., Cohen, T., Herzog, Y., Neufeld, G. (2000) Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. J Biol Chem 275, 18040–18045.
Herzog, Y., Kalcheim, C., Kahane, N., Reshef, R., Neufeld, G. (2001) Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech Dev 109, 115–119.
Yuan, L., Moyon, D., Pardanaud, L., (2002) Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 129, 4797–4806.
Karkkainen, M. J., Saaristo, A., Jussila, L., (2001) A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci U S A 98, 12677–12682.
Takashima, S., Kitakaze, M., Asakura, M., (2002) Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci U S A 99, 3657–3662.
Shen, J., Samul, R., Zimmer, J., (2004) Deficiency of neuropilin 2 suppresses VEGF-induced retinal neovascularization. Mol Med 10, 12–18.
Comoglio, P. M., Trusolino, L. (2002) Invasive growth: from development to metastasis. J Clin Invest 109, 857–862.
Giordano, S., Corso, S., Conrotto, P., (2002) The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol 4, 720–724.
Gu, C., Yoshida, Y., Livet, J., (2005) Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. Science 307, 265–268.
Toyofuku, T., Zhang, H., Kumanogoh, A., (2004) Dual roles of Sema6D in cardiac morphogenesis through region-specific association of its receptor, Plexin-A1, with off-track and vascular endothelial growth factor receptor type 2. Genes Dev 18, 435–447.
Takahashi, T., Fournier, A., Nakamura, F., (1999) Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. Cell 99, 59–69.
Tamagnone, L., Artigiani, S., Chen, H., (1999) Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 99, 71–80.
Suto, F., Murakami, Y., Nakamura, F., Goshima, Y., Fujisawa, H. (2003) Identification and characterization of a novel mouse plexin, plexin-A4. Mech Dev 120, 385–396.
Takahashi, T., Strittmatter, S. M. (2001) Plexina1 autoinhibition by the plexin sema domain. Neuron 29, 429–439.
Iso, T., Hamamori, Y., Kedes, L. (2003) Notch signaling in vascular development. Arterioscler Thromb Vasc Biol 23, 543–553.
Shawber, C. J., Das, I., Francisco, E., Kitajewski, J. (2003) Notch signaling in primary endothelial cells. Ann N Y Acad Sci 995, 162–170.
Uyttendaele, H., Ho, J., Rossant, J., Kitajewski, J. (2001) Vascular patterning defects associated with expression of activated Notch4 in embryonic endothelium. Proc Natl Acad Sci U S A 98, 5643–5648.
Mailhos, C., Modlich, U., Lewis, J., Harris, A., Bicknell, R., Ish-Horowicz, D. (2001) Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 69, 135–144.
Shutter, J. R., Scully, S., Fan, W., (2000) Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev 14, 1313–1318.
Villa, N., Walker, L., Lindsell, C. E., (2001) Vascular expression of Notch pathway receptors and ligands is restricted to arterial vessels. Mech Dev 108, 161–164.
Kalaria, R. N., Low, W. C., Oakley, A. E., et al. (2002) CADASIL and genetics of cerebral ischaemia. J Neural Transm Suppl, 75–90.
Xue, Y., Gao, X., Lindsell, C. E., (1999) Embryonic lethality and vascular defects in mice lacking the Notch ligand Jagged1. Hum Mol Genet 8, 723–730.
Hrabe de Angelis, M., McIntyre, J., 2nd, Gossler, A. (1997) Maintenance of somite borders in mice requires the Delta homologue DII1. Nature 386, 717–721.
Krebs, L. T., Xue, Y., Norton, C. R., (2000) Notch signaling is essential for vascular morphogenesis in mice. Genes Dev 14, 1343–1352.
Huppert, S. S., Le, A., Schroeter, E. H., (2000) Embryonic lethality in mice homozygous for a processing-deficient allele of Notch1. Nature 405, 966–970.
Limbourg, F. P., Takeshita, K., Radtke, F., Bronson, R. T., Chin, M. T., Liao, J. K. (2005) Essential role of endothelial Notch1 in angiogenesis. Circulation 111, 1826–1832.
Fischer, A., Schumacher, N., Maier, M., Sendtner, M., Gessler, M. (2004) The Notch target genes Hey1 and Hey2 are required for embryonic vascular development. Genes Dev 18, 901–911.
Carlson, T. R., Yan, Y., Wu, X., (2005) Endothelial expression of constitutively active Notch4 elicits reversible arteriovenous malformations in adult mice. Proc Natl Acad Sci U S A 102, 9884–9889.
Holder, N., Klein, R. (1999) Eph receptors and ephrins: effectors of morphogenesis. Development 126, 2033–2044.
Adams, R. H., Klein, R. (2000) Eph receptors and ephrin ligands, essential mediators of vascular development. Trends Cardiovasc Med 10, 183–188.
Zhang, J., Hughes, S. (2006) Role of the ephrin and Eph receptor tyrosine kinase families in angiogenesis and development of the cardiovascular system. J Pathol 208, 453–461.
Wilkinson, D. G. (2001) Multiple roles of EPH receptors and ephrins in neural development. Nat Rev Neurosci 2, 155–164.
Kullander, K., Klein, R. (2002) Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 3, 475–486.
Palmer, A., Klein, R. (2003) Multiple roles of ephrins in morphogenesis, neuronal networking, and brain function. Genes Dev 17, 1429–1450.
Gale, N. W., Holland, S. J., Valenzuela, D. M., (1996) Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 17, 9–19.
Adams, R. H., Diella, F., Hennig, S., Helmbacher, F., Deutsch, U., Klein, R. (2001) The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration. Cell 104, 57–69.
Wang, H. U., Chen, Z. F., Anderson, D. J. (1998) Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93, 741–753.
Gerety, S. S., Wang, H. U., Chen, Z. F., Anderson, D. J. (1999) Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 4, 403–414.
Adams, R. H., Wilkinson, G. A., Weiss, C., (1999) Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, sprouting angiogenesis. Genes Dev 13, 295–306.
Pandey, A., Shao, H., Marks, R. M., Polverini, P. J., Dixit, V. M. (1995) Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science 268, 567–569.
Stein, E., Lane, A. A., Cerretti, D. P., (1998) Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, assembly responses. Genes Dev 12, 667–678.
Ogawa, K., Pasqualini, R., Lindberg, R. A., Kain, R., Freeman, A. L., Pasquale, E. B. (2000) The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19, 6043–6052.
Brantley, D. M., Cheng, N., Thompson, E. J., (2002) Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21, 7011–7026.
Cheng, N., Brantley, D. M., Chen, J. (2002) The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev 13, 75–85.
Cheng, N., Brantley, D. M., Liu, H., (2002) Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 1, 2–11.
Wilson, B. D., Ii, M., Park, K. W., (2006) Netrins promote developmental and therapeutic angiogenesis. Science 313, 640–644.
Lu, X., Le Noble, F., Yuan, L., (2004) The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature 432, 179–186.
Klagsbrun, M., Eichmann, A. (2005) A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis. Cytokine Growth Factor Rev 16, 535–548.
Park, K. W., Crouse, D., Lee, M., (2004) The axonal attractant Netrin-1 is an angiogenic factor. Proc Natl Acad Sci U S A 101, 16210–16215.
Huminiecki, L., Bicknell, R. (2000) In silico cloning of novel endothelial-specific genes. Genome Res 10, 1796–1806.
Suchting, S., Heal, P., Tahtis, K., Stewart, L. M., Bicknell, R. (2005) Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration. FASEB J 19, 121–123.
Wang, B., Xiao, Y., Ding, B. B., (2003) Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Cell 4, 19–29.
Park, K. W., Morrison, C. M., Sorensen, L. K., (2003) Robo4 is a vascular-specific receptor that inhibits endothelial migration. Dev Biol 261, 251–267.
Bedell, V. M., Yeo, S. Y., Park, K. W., (2005) Roundabout4 is essential for angiogenesis in vivo. Proc Natl Acad Sci U S A 102, 6373–6378.
Pola, R., Ling, L. E., Silver, M., (2001) The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med 7, 706–711.
Lawson, N. D., Vogel, A. M., Weinstein, B. M. (2002) sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. Dev Cell 3, 127–136.
Hacohen, N., Kramer, S., Sutherland, D., Hiromi, Y., Krasnow, M. A. (1998) sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 92, 253–263.
Tefft, J. D., Lee, M., Smith, S., (1999) Conserved function of mSpry-2, a murine homolog of Drosophila sprouty, which negatively modulates respiratory organogenesis. Curr Biol 9, 219–222.
de Maximy, A. A., Nakatake, Y., Moncada, S., Itoh, N., Thiery, J. P., Bellusci, S. (1999) Cloning and expression pattern of a mouse homologue of Drosophila sprouty in the mouse embryo. Mech Dev 81, 213–216.
Minowada, G., Jarvis, L. A., Chi, C. L., (1999) Vertebrate Sprouty genes are induced by FGF signaling and can cause chondrodysplasia when overexpressed. Development 126, 4465–4475.
Sutherland, D., Samakovlis, C., Krasnow, M. A. (1996) branchless encodes a Drosophila FGF homolog that controls tracheal cell migration and the pattern of branching. Cell 87, 1091–1101.
Metzger, R. J., Krasnow, M. A. (1999) Genetic control of branching morphogenesis. Science 284, 1635–1639.
Klambt, C., Glazer, L., Shilo, B. Z. (1992) breathless, a Drosophila FGF receptor homolog, is essential for migration of tracheal and specific midline glial cells. Genes Dev 6, 1668–1678.
Lee, T., Hacohen, N., Krasnow, M., Montell, D. J. (1996) Regulated Breathless receptor tyrosine kinase activity required to pattern cell migration and branching in the Drosophila tracheal system. Genes Dev 10, 2912–2921.
Lee, S. H., Schloss, D. J., Jarvis, L., Krasnow, M. A., Swain, J. L. (2001) Inhibition of angiogenesis by a mouse sprouty protein. J Biol Chem 276, 4128–4133.</bh>
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Ahmed, Z., Bicknell, R. (2009). Angiogenic Signalling Pathways. In: Murray, C., Martin, S. (eds) Angiogenesis Protocols. Methods in Molecular Biology, vol 467. Humana Press. https://doi.org/10.1007/978-1-59745-241-0_1
Download citation
DOI: https://doi.org/10.1007/978-1-59745-241-0_1
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-58829-907-9
Online ISBN: 978-1-59745-241-0
eBook Packages: Springer Protocols